Your browser is no longer supported. Please, upgrade your browser.
NBIX [NASD]
Neurocrine Biosciences, Inc.
Index- P/E23.13 EPS (ttm)4.16 Insider Own1.30% Shs Outstand93.40M Perf Week3.43%
Market Cap8.94B Forward P/E20.24 EPS next Y4.75 Insider Trans-27.93% Shs Float91.22M Perf Month4.27%
Income407.30M PEG0.70 EPS next Q0.54 Inst Own96.40% Short Float7.67% Perf Quarter-11.60%
Sales1.05B P/S8.55 EPS this Y977.20% Inst Trans0.09% Short Ratio5.71 Perf Half Y-6.19%
Book/sh12.06 P/B7.97 EPS next Y46.85% ROA26.60% Target Price127.38 Perf Year-5.38%
Cash/sh8.61 P/C11.16 EPS next 5Y33.20% ROE47.10% 52W Range86.02 - 136.26 Perf YTD0.32%
Dividend- P/FCF41.09 EPS past 5Y42.90% ROI30.80% 52W High-29.43% Beta0.77
Dividend %- Quick Ratio5.30 Sales past 5Y121.20% Gross Margin99.00% 52W Low11.79% ATR3.49
Employees845 Current Ratio5.40 Sales Q/Q1.60% Oper. Margin13.80% RSI (14)50.48 Volatility3.17% 3.67%
OptionableYes Debt/Eq0.28 EPS Q/Q923.60% Profit Margin38.90% Rel Volume0.45 Prev Close94.85
ShortableYes LT Debt/Eq0.28 EarningsMay 05 AMC Payout0.00% Avg Volume1.23M Price96.16
Recom2.00 SMA201.52% SMA50-4.12% SMA200-8.39% Volume555,183 Change1.38%
Feb-02-21Initiated Raymond James Outperform $163
Sep-30-20Initiated The Benchmark Company Hold
Aug-04-20Downgrade JP Morgan Overweight → Neutral $136
Jun-29-20Downgrade Goldman Buy → Neutral $135
Jun-09-20Initiated Wedbush Outperform $147
Mar-06-20Initiated Citigroup Buy $124
Feb-27-20Initiated Barclays Equal Weight $105
Feb-24-20Initiated William Blair Outperform
Feb-06-20Initiated Mizuho Neutral
Feb-05-20Reiterated H.C. Wainwright Buy $102 → $125
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $110
Aug-07-19Initiated RBC Capital Mkts Outperform $118
Jul-16-19Initiated Oppenheimer Outperform $100
Jun-05-19Initiated Guggenheim Neutral
May-21-19Initiated Credit Suisse Outperform $95
Apr-22-19Upgrade JP Morgan Neutral → Overweight
Apr-12-19Initiated Evercore ISI Outperform
Feb-06-19Reiterated BofA/Merrill Buy $124 → $117
Jan-23-19Downgrade JP Morgan Overweight → Neutral
Dec-13-18Initiated Goldman Buy $103
Apr-19-21 03:51PM  
Apr-16-21 09:00AM  
Apr-14-21 04:01PM  
Apr-08-21 04:01PM  
Mar-26-21 09:33AM  
Mar-25-21 04:01PM  
03:34PM  
Mar-24-21 06:35PM  
Mar-22-21 07:21AM  
Mar-20-21 11:00AM  
Mar-18-21 06:02PM  
Mar-09-21 04:01PM  
Mar-02-21 08:53AM  
07:30AM  
Feb-23-21 04:01PM  
Feb-04-21 11:31PM  
05:55PM  
04:49PM  
04:01PM  
02:45PM  
04:00AM  
Feb-02-21 04:01PM  
Jan-28-21 12:32PM  
Jan-20-21 04:01PM  
Jan-08-21 10:15AM  
07:30AM  
Jan-04-21 04:01PM  
Dec-22-20 04:17PM  
Dec-21-20 11:36AM  
04:22AM  
Dec-11-20 08:58AM  
Dec-09-20 07:51AM  
Nov-19-20 09:00AM  
08:00AM  
Nov-13-20 07:29AM  
Nov-10-20 04:00PM  
Nov-09-20 05:15PM  
04:54PM  
04:01PM  
02:45PM  
09:00AM  
Nov-06-20 10:18AM  
Nov-04-20 11:10AM  
Nov-02-20 12:31PM  
11:45AM  
Oct-19-20 07:56AM  
Oct-15-20 10:45AM  
Oct-08-20 08:00AM  
Oct-07-20 06:45AM  
Oct-06-20 04:01PM  
Sep-30-20 09:35AM  
Sep-28-20 04:01PM  
Sep-14-20 01:24PM  
08:43AM  
08:30AM  
Sep-11-20 03:27PM  
11:36AM  
11:34AM  
11:32AM  
Sep-09-20 09:48PM  
03:12PM  
Sep-08-20 04:01PM  
Sep-03-20 04:06PM  
Sep-02-20 04:01PM  
Aug-28-20 10:11AM  
Aug-04-20 09:30AM  
08:38AM  
06:34AM  
Aug-03-20 05:15PM  
04:37PM  
04:01PM  
Jul-30-20 04:01PM  
Jul-27-20 12:31PM  
Jul-13-20 07:16PM  
04:01PM  
Jul-01-20 07:00AM  
Jun-25-20 12:17PM  
Jun-17-20 04:04PM  
Jun-16-20 07:00AM  
Jun-15-20 04:01PM  
Jun-08-20 11:01AM  
Jun-05-20 11:26AM  
Jun-04-20 04:01PM  
Jun-03-20 01:44AM  
Jun-01-20 11:46AM  
May-29-20 04:13PM  
May-26-20 04:01PM  
09:39AM  
May-23-20 08:00AM  
May-18-20 12:16PM  
May-14-20 07:29PM  
06:27AM  
May-13-20 04:01PM  
02:58PM  
02:38PM  
May-12-20 04:55PM  
May-11-20 04:01PM  
May-07-20 08:09PM  
05:30PM  
04:01PM  
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for the treatment of rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for the treatment of anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL A Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Option Exercise35.991,70061,18333,610Feb 12 08:27 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 10Sale119.961,700203,92632,510Feb 12 08:27 PM
Lippoldt DarinChief Legal OfficerFeb 09Option Exercise35.9936,1941,302,62264,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 09Sale116.1736,1944,204,83134,361Feb 09 09:16 PM
Lippoldt DarinChief Legal OfficerFeb 08Sale116.723,407397,67431,914Feb 09 09:16 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 08Sale116.7510,4661,221,864446,144Feb 09 09:17 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 08Sale116.692,708315,99983,456Feb 09 09:18 PM
ROBERTS EIRYChief Medical OfficerFeb 08Sale116.782,363275,94417,231Feb 09 09:21 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 08Sale116.813,261380,92930,437Feb 09 09:20 PM
Cooke JulieChief Human Resources OfficerFeb 08Sale116.731,338156,18912,915Feb 09 09:24 PM
BENEVICH ERICChief Commercial OfficerFeb 08Sale116.824,270498,84218,018Feb 09 09:26 PM
ABERNETHY MATTChief Financial OfficerFeb 08Sale116.822,910339,94213,043Feb 09 09:30 PM
Bozigian Haig P.Chief Development OfficerFeb 08Sale116.803,842448,749154,934Feb 09 09:27 PM
Gano KyleChief Business Development OffFeb 08Sale116.853,693431,518102,406Feb 09 09:42 PM
Gano KyleChief Business Development OffFeb 05Sale114.002,677305,18498,663Feb 09 09:42 PM
Bozigian Haig P.Chief Development OfficerFeb 05Sale113.7970480,109153,328Feb 09 09:27 PM
BENEVICH ERICChief Commercial OfficerFeb 05Sale114.0380992,24716,434Feb 09 09:26 PM
Cooke JulieChief Human Resources OfficerFeb 05Sale113.8660568,88612,125Feb 09 09:24 PM
Lloyd-Smith MalcolmChief Regulatory OfficerFeb 05Sale114.1586598,73929,675Feb 09 09:20 PM
Grigoriadis Dimitri E.Chief Research OfficerFeb 05Sale113.7660568,82382,169Feb 09 09:18 PM
GORMAN KEVIN CHARLESChief Executive OfficerFeb 05Sale114.162,422276,504443,249Feb 09 09:17 PM
Lippoldt DarinChief Legal OfficerFeb 05Sale114.0560569,00330,627Feb 09 09:16 PM
BENEVICH ERICChief Commercial OfficerJan 26Option Exercise41.7830012,53416,105Jan 27 08:58 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Option Exercise35.991,10039,58929,602Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 26Sale120.0040048,00015,705Jan 27 08:58 PM
LYONS GARY ADirectorJan 26Sale120.0040048,000223,697Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 26Sale119.971,100131,96529,002Jan 27 09:30 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Option Exercise34.4617,570605,47037,960Jan 27 09:30 PM
BENEVICH ERICChief Commercial OfficerJan 25Option Exercise41.783,477145,26920,882Jan 27 08:58 PM
BENEVICH ERICChief Commercial OfficerJan 25Sale120.035,077609,37115,805Jan 27 08:58 PM
LYONS GARY ADirectorJan 25Sale120.031,600192,047224,097Jan 27 09:53 PM
Lloyd-Smith MalcolmChief Regulatory OfficerJan 25Sale119.9717,5702,107,81229,002Jan 27 09:30 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 08Option Exercise8.65308,2502,667,797605,872Jan 12 04:16 PM
ROBERTS EIRYChief Medical OfficerJan 08Sale111.062,632292,29715,845Jan 12 04:17 PM
GORMAN KEVIN CHARLESChief Executive OfficerJan 08Sale110.22308,25033,973,877441,071Jan 12 04:16 PM
ABERNETHY MATTChief Financial OfficerDec 01Sale94.661,645155,72111,494Dec 02 04:12 PM
BENEVICH ERICChief Commercial OfficerNov 12Sale90.712,257204,72317,405Nov 16 06:27 PM
ROBERTS EIRYChief Medical OfficerNov 12Sale90.742,257204,81013,477Nov 16 06:23 PM
Lloyd-Smith MalcolmChief Regulatory OfficerNov 12Sale90.732,257204,77629,002Nov 16 06:21 PM
Lippoldt DarinChief Legal OfficerNov 12Sale90.722,257204,75530,082Nov 16 06:20 PM
Grigoriadis Dimitri E.Chief Research OfficerNov 12Sale90.732,257204,78481,624Nov 16 06:19 PM
GORMAN KEVIN CHARLESChief Executive OfficerNov 12Sale90.783,390307,748441,071Nov 16 06:16 PM
Gano KyleChief Business Development OffNov 12Sale90.732,257204,77098,028Nov 16 06:11 PM
Cooke JulieChief Human Resources OfficerNov 12Sale90.732,257204,77811,580Nov 16 06:10 PM
Bozigian Haig P.Chief Development OfficerNov 12Sale90.742,257204,806152,694Nov 16 06:08 PM
ABERNETHY MATTChief Financial OfficerNov 12Sale90.742,257204,81010,014Nov 16 06:02 PM
BENEVICH ERICChief Commercial OfficerNov 02Option Exercise35.9920,595741,21435,969Nov 04 06:09 PM
BENEVICH ERICChief Commercial OfficerNov 02Sale96.5320,5951,987,97215,374Nov 04 06:09 PM
Cooke JulieChief Human Resources OfficerOct 02Sale95.2698794,0229,549Oct 06 04:05 PM
ROBERTS EIRYChief Medical OfficerAug 05Sale118.842,257268,22511,446Aug 07 07:51 PM
Lloyd-Smith MalcolmChief Regulatory OfficerAug 05Sale118.862,257268,27726,971Aug 07 07:47 PM
Lippoldt DarinChief Legal OfficerAug 05Sale118.872,257268,29728,051Aug 07 07:40 PM
Grigoriadis Dimitri E.Chief Research OfficerAug 05Sale118.832,257268,20079,593Aug 07 07:36 PM
GORMAN KEVIN CHARLESChief Executive OfficerAug 05Sale118.913,390403,101438,021Aug 07 07:29 PM
Gano KyleChief Business Development OffAug 05Sale118.872,257268,28695,997Aug 07 07:24 PM
Cooke JulieChief Human Resources OfficerAug 05Sale118.912,257268,3838,661Aug 07 07:21 PM
Bozigian Haig P.Chief Development OfficerAug 05Sale118.892,257268,324150,663Aug 07 07:14 PM
BENEVICH ERICChief Commercial OfficerAug 05Sale118.852,257268,25415,374Aug 07 06:35 PM
ABERNETHY MATTChief Financial OfficerAug 05Sale118.902,257268,3567,983Aug 07 06:22 PM
Lippoldt DarinChief Legal OfficerJul 09Option Exercise35.991,65759,63527,678Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJul 09Sale136.021,657225,38626,021Jul 10 04:26 PM
Lippoldt DarinChief Legal OfficerJun 23Option Exercise32.995,000164,95031,021Jun 25 04:15 PM
ROBERTS EIRYChief Medical OfficerJun 23Option Exercise77.815,000389,05014,416Jun 25 04:19 PM
ROBERTS EIRYChief Medical OfficerJun 23Sale130.005,000650,0009,416Jun 25 04:19 PM
Lippoldt DarinChief Legal OfficerJun 23Sale130.005,000650,00026,021Jun 25 04:15 PM
Grigoriadis Dimitri E.Chief Research OfficerJun 11Option Exercise35.905,571199,97677,563Jun 15 05:31 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 19Sale126.5542,7495,409,93371,992May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Option Exercise32.995,000164,95031,021May 20 07:15 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Option Exercise35.9910,000359,900114,741May 20 06:59 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 18Sale119.9810,0001,199,800104,741May 20 06:59 PM
Lippoldt DarinChief Legal OfficerMay 18Sale120.005,000600,00026,021May 20 07:15 PM
Bozigian Haig P.Chief Development OfficerMay 12Option Exercise63.1061,5553,884,054167,204May 14 08:09 PM
Bozigian Haig P.Chief Development OfficerMay 12Sale114.9461,5557,075,396148,633May 14 08:09 PM
ABERNETHY MATTChief Financial OfficerMay 07Option Exercise73.6015,0001,104,00020,953May 11 08:17 PM
ABERNETHY MATTChief Financial OfficerMay 07Sale110.2115,0001,653,1345,953May 11 08:17 PM
Grigoriadis Dimitri E.Chief Research OfficerMay 07Sale105.448,682915,454104,741May 11 08:06 PM
SHERWIN STEPHEN ADirectorApr 28Sale99.3917,6871,757,96629,861Apr 30 04:27 PM
ABERNETHY MATTChief Financial OfficerApr 28Sale102.491,741178,4355,953Apr 30 04:25 PM
GORMAN KEVIN CHARLESChief Executive OfficerApr 24Sale99.452,906289,016434,971Apr 28 08:41 PM
Gano KyleChief Business Development OffApr 24Sale99.471,934192,37793,967Apr 28 08:40 PM
Cooke JulieChief Human Resources OfficerApr 24Sale99.461,934192,3646,631Apr 28 08:38 PM
Bozigian Haig P.Chief Development OfficerApr 24Sale99.461,934192,351148,633Apr 28 08:35 PM
BENEVICH ERICChief Commercial OfficerApr 24Sale99.451,934192,33813,344Apr 28 08:33 PM
ABERNETHY MATTChief Financial OfficerApr 24Sale99.521,934192,4677,694Apr 28 08:32 PM
ROBERTS EIRYChief Medical OfficerApr 24Sale99.471,934192,3769,416Apr 28 08:46 PM
Lloyd-Smith MalcolmChief Regulatory OfficerApr 24Sale99.451,934192,32924,941Apr 28 08:44 PM
Lippoldt DarinChief Legal OfficerApr 24Sale99.491,934192,41626,021Apr 28 08:43 PM
Grigoriadis Dimitri E.Chief Research OfficerApr 24Sale99.411,934192,258113,423Apr 28 08:42 PM